viewRedx Pharma PLC

Redx Pharma plc - Redx to present at 2019 Biotech Showcase event

RNS Number : 2804L
Redx Pharma plc
03 January 2019



("Redx" or "the Company")


Redx to present at 2019 Biotech Showcase event in San Francisco


Alderley Park, 3 January 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that Lisa Anson, Chief Executive Officer and Dr Andrew Saunders, Chief Medical Officer will be presenting at Biotech Showcase in San Francisco, which runs from 7 - 9 January 2019.  Lisa Anson joined Redx from a senior role at AstraZeneca in mid-2018 with a remit to relaunch the Company. This will be the first time that she will present the Company in the US as Redx's CEO. Andrew Saunders will provide an update on the Company's clinical Oncology programme. The team will also be joined by Dr. Peter Bunyard, Head of Fibrosis, following the announcement of the Company's first fibrosis development candidate, RXC006, in November 2018.


Redx's presentation will take place at 3pm PST on Tuesday 8 January 2019 at the Hilton, Union Square in San Francisco, California, Track: Yosemite A (Ballroom Level).


Lisa Anson, Chief Executive Officer, Redx Pharma plc commented: "I am delighted that Redx has been asked to present at the Biotech Showcase event in January. The event is a great opportunity to share with potential US investors and partners how far we have progressed in 2018 and our forthcoming milestones and plans for 2019."


For further information, please contact:

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

Andrew Saunders, Chief Medical Officer




Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

 T: +44 20 7894 7000

Phil Davies




WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson




FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert



About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.


If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Redx Pharma PLC

Price: 12.5

Market: AIM
Market Cap: £23.75 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role. Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior...

on 19/7/18